Regulus Therapeutics Inc (RGLS) stock is down 13.79% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With RGLS Stock Today?
Regulus Therapeutics Inc (RGLS) stock is trading at $1.00 as of 2:05 PM on Monday, Jun 14, a loss of -$0.04, or -3.85% from the previous closing price of $1.04. The stock has traded between $0.98 and $1.05 so far today. Volume today is above average. So far 5,155,492 shares have traded compared to average volume of 4,091,086 shares.
To see the top 5 stocks in the Biotechnology industry click here.
More About Regulus Therapeutics Inc
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.
Click Here to get the full Stock Score Report on Regulus Therapeutics Inc (RGLS) Stock.
